Ningbo Shuangcheng Passes U.S. FDA Inspection
2020-04-28 09:50
Ningbo Shuangcheng Pharmaceuticals Ltd (“NBSP”) has received the unannounced on-site inspection by the U.S. FDA from 14 October to 18 October 2019, regarding the submitted product of Memantine Hydrochloride Tablets.
In December of the same year, NBSP has received the acceptance letter from the U.S. FDA that the facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).
In December of the same year, NBSP has received the acceptance letter from the U.S. FDA that the facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).
